Literature DB >> 26113408

High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma.

Bin Zhang1, Bo Cheng1, Feng-Sheng Li1, Jian-Hua Ding1, Ying-Ying Feng1, Guang-Zuan Zhuo1, Hua-Feng Wei2, Ke Zhao3.   

Abstract

The ectonucleotidase CD39 is pivotal in the conversion of immunostimulatory adenosine triphosphate (ATP) into immunosuppressive adenosine which potently inhibits host immune responses against cancer. This study investigated the expression level and prognostic significance of CD39 in human rectal adenocarcinoma. Our data demonstrated that CD39 staining strongly marked malignant epithelial cells where the protein and messenger RNA (mRNA) expression levels of CD39 were significantly increased compared with paracancerous controls. In addition to primary tumors, CD39 was also abundantly expressed in liver metastases and tumor-draining lymph nodes from metastatic rectal adenocarcinoma. Although patients with higher CD39 density in tumor cells were more likely to have favorable characteristics (early TNM and N stages) and overall survival, the singular parameter cannot be used as an independent factor for predicting patients' prognosis. Intriguingly, combined analysis of CD39 and CD73 expression was more efficient to foretell patient's outcome where patients with increased CD73 but decreased CD39 levels displayed a worst prognosis. Taken together, the current study revealed that malignant epithelial cells of human rectal adenocarcinoma strongly express CD39 that may play a potential role in the tumor invasion and metastasis. Although high expression of CD39 in tumor cells is correlated with favorable clinical outcome, the combination of CD39 and CD73 expression may have a better prognostic value.

Entities:  

Keywords:  CD39; CD73; ENTPD1; Rectal adenocarcinoma; Survival

Mesh:

Substances:

Year:  2015        PMID: 26113408     DOI: 10.1007/s13277-015-3683-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  High expression of CD73 as a poor prognostic biomarker in human colorectal cancer.

Authors:  Xian-Rui Wu; Xiao-Sheng He; Yu-Feng Chen; Rui-Xue Yuan; Yang Zeng; Lei Lian; Yi-Feng Zou; Nan Lan; Xiao-Jian Wu; Ping Lan
Journal:  J Surg Oncol       Date:  2012-01-27       Impact factor: 3.454

2.  Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

Authors:  Sebastian F M Häusler; Itsaso Montalbán del Barrio; Jenny Strohschein; P Anoop Chandran; Jörg B Engel; Arnd Hönig; Monika Ossadnik; Evi Horn; Birgitt Fischer; Mathias Krockenberger; Stefan Heuer; Ahmed Adel Seida; Markus Junker; Hermann Kneitz; Doris Kloor; Karl-Norbert Klotz; Johannes Dietl; Jörg Wischhusen
Journal:  Cancer Immunol Immunother       Date:  2011-06-03       Impact factor: 6.968

3.  Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Authors:  Jeremy Bastid; Anne Regairaz; Nathalie Bonnefoy; Cécile Déjou; Jérôme Giustiniani; Caroline Laheurte; Stéphanie Cochaud; Emilie Laprevotte; Elisa Funck-Brentano; Patrice Hemon; Laurent Gros; Nicole Bec; Christian Larroque; Gilles Alberici; Armand Bensussan; Jean-François Eliaou
Journal:  Cancer Immunol Res       Date:  2014-11-17       Impact factor: 11.151

4.  CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.

Authors:  Xiaofeng Sun; Yan Wu; Wenda Gao; Keiichi Enjyoji; Eva Csizmadia; Christa E Müller; Takashi Murakami; Simon C Robson
Journal:  Gastroenterology       Date:  2010-06-25       Impact factor: 22.682

Review 5.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

6.  Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.

Authors:  Lili Feng; Xiaofeng Sun; Eva Csizmadia; Lihui Han; Shu Bian; Takashi Murakami; Xin Wang; Simon C Robson; Yan Wu
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

Review 7.  Targeting cancer-derived adenosine: new therapeutic approaches.

Authors:  Arabella Young; Deepak Mittal; John Stagg; Mark J Smyth
Journal:  Cancer Discov       Date:  2014-07-17       Impact factor: 39.397

Review 8.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

9.  Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.

Authors:  Bin Zhang; Zhijun Wang; Liangliang Wu; Meng Zhang; Wei Li; Jianhua Ding; Jun Zhu; Huafeng Wei; Ke Zhao
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

10.  Ensemble of gene signatures identifies novel biomarkers in colorectal cancer activated through PPARγ and TNFα signaling.

Authors:  Stefano Maria Pagnotta; Carmelo Laudanna; Massimo Pancione; Lina Sabatino; Carolina Votino; Andrea Remo; Luigi Cerulo; Pietro Zoppoli; Erminia Manfrin; Vittorio Colantuoni; Michele Ceccarelli
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more
  17 in total

Review 1.  Purinergic drug targets for gastrointestinal disorders.

Authors:  Geoffrey Burnstock; Kenneth A Jacobson; Fievos L Christofi
Journal:  Curr Opin Pharmacol       Date:  2017-11-14       Impact factor: 5.547

2.  Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Authors:  Xian-Yang Li; Achim K Moesta; Christos Xiao; Kyohei Nakamura; Mika Casey; Haiyan Zhang; Jason Madore; Ailin Lepletier; Amelia Roman Aguilera; Ashmitha Sundarrajan; Celia Jacoberger-Foissac; Clifford Wong; Tracy Dela Cruz; Megan Welch; Alana G Lerner; Bradley N Spatola; Vanessa B Soros; John Corbin; Ana C Anderson; Maike Effern; Michael Hölzel; Simon C Robson; Rebecca L Johnston; Nicola Waddell; Corey Smith; Tobias Bald; Nishamol Geetha; Courtney Beers; Michele W L Teng; Mark J Smyth
Journal:  Cancer Discov       Date:  2019-11-07       Impact factor: 39.397

Review 3.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

4.  Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Authors:  Paul A Beavis; Melissa A Henderson; Lauren Giuffrida; Jane K Mills; Kevin Sek; Ryan S Cross; Alexander J Davenport; Liza B John; Sherly Mardiana; Clare Y Slaney; Ricky W Johnstone; Joseph A Trapani; John Stagg; Sherene Loi; Lev Kats; David Gyorki; Michael H Kershaw; Phillip K Darcy
Journal:  J Clin Invest       Date:  2017-02-06       Impact factor: 14.808

Review 5.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  Is the regulation by miRNAs of NTPDase1 and ecto-5'-nucleotidase genes involved with the different profiles of breast cancer subtypes?

Authors:  Fernanda Cardoso da Silva; Angelo Borges de Melo Neto; Christina Aparecida Martins; Thaís Cunha de Sousa Cardoso; Matheus de Souza Gomes; Thaise Gonçalves de Araújo; Cristina Ribas Fürstenau
Journal:  Purinergic Signal       Date:  2021-11-05       Impact factor: 3.765

7.  Comment on "High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma".

Authors:  Luca Antonioli; Antonello di Paolo; Matteo Fornai; Romano Danesi; Corrado Blandizzi
Journal:  Tumour Biol       Date:  2015-09-17

8.  The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

Authors:  Sènan M d'Almeida; Gilles Kauffenstein; Charlotte Roy; Laetitia Basset; Loukas Papargyris; Daniel Henrion; Véronique Catros; Norbert Ifrah; Philippe Descamps; Anne Croue; Pascale Jeannin; Marc Grégoire; Yves Delneste; Julie Tabiasco
Journal:  Oncoimmunology       Date:  2016-04-28       Impact factor: 8.110

9.  Identification of differentially expressed genes and signaling pathways in papillary thyroid cancer: a study based on integrated microarray and bioinformatics analysis.

Authors:  Tuanqi Sun; Qing Guan; Yunjun Wang; Kai Qian; Wenyu Sun; Qinghai Ji; Yi Wu; Kai Guo; Jun Xiang
Journal:  Gland Surg       Date:  2021-02

10.  CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.

Authors:  Lauren Giuffrida; Kevin Sek; Melissa A Henderson; Junyun Lai; Amanda X Y Chen; Deborah Meyran; Kirsten L Todd; Emma V Petley; Sherly Mardiana; Christina Mølck; Gregory D Stewart; Benjamin J Solomon; Ian A Parish; Paul J Neeson; Simon J Harrison; Lev M Kats; Imran G House; Phillip K Darcy; Paul A Beavis
Journal:  Nat Commun       Date:  2021-05-28       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.